Synthesis and Bioactivity Evaluation of Novel Thiochroman-4-One Derivatives Incorporating Carboxamide and 1, 3, 4-Thiadiazole Thioether Moieties

Table 1

Preliminary antibacterial activity of the target compounds against Xoo and Xac at 200 and 100 μg/mL.

Compounds	Inhibition rate (%)
	Xoo		Xac
	200 μg/mL	100 μg/mL	200 μg/mL	100 μg/mL
5a	100 ± 2.13	94 ± 1.25	90 ± 0.28	78 ± 1.01
5b	92 ± 1.14	78 ± 2.07	86 ± 2.22	70 ± 1.27
5c	81 ± 2.19	70 ± 1.64	74 ± 2.08	61 ± 2.21
5d	60 ± 1.95	44 ± 1.47	51 ± 1.18	40 ± 1.27
5e	64 ± 1.54	50 ± 1.99	57 ± 3.12	45 ± 2.19
5f	90 ± 1.17	75 ± 1.54	80 ± 2.21	61 ± 1.31
5g	74 ± 1.41	60 ± 2.17	68 ± 1.14	54 ± 1.29
5h	68 ± 1.54	54 ± 0.59	60 ± 1.24	48 ± 2.20
5i	51 ± 1.19	38 ± 1.02	47 ± 1.14	31 ± 2.01
5j	54 ± 2.08	41 ± 1.28	51 ± 1.98	39 ± 1.52
5k	45 ± 2.21	32 ± 1.59	40 ± 1.21	30 ± 2.06
5l	37 ± 1.27	28 ± 2.28	32 ± 0.98	20 ± 0.94
5m	30 ± 1.08	20 ± 2.21	25 ± 1.26	14 ± 2.19
5n	24 ± 1.26	16 ± 1.21	16 ± 1.24	8 ± 1.54
5o	28 ± 1.11	18 ± 1.24	21 ± 1.59	12 ± 2.20
Bismerthiazol	70 ± 0.89	52 ± 1.62	57 ± 5.56	35 ± 6.76
Thiadiazole copper	63 ± 2.71	45 ± 2.65	35 ± 4.31	15 ± 2.11